Literature DB >> 7639016

Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them.

L Kutinová1, V Ludvíková, V Simonová, M Otavová, J Krystofová, P Hainz, M Press, D Kunke, V Vonka.   

Abstract

Three vaccinia virus strains (Praha, DD--a DRYVAX Wyeth vaccine-derived virus-and LIVP) were examined for growth in various cell cultures and for virulence and immunogenicity in mice. The viruses did not differ by their growth rates in monkey kidney cells (CV-1), human diploid cells (LEP), rat TK cells (RAT 2) or primary dog kidney cells. The immunogenicity of Praha and DD viruses was similar, the virus LIVP was somewhat more immunogenic. In terms of virulence in 3-day-old mice, the DD virus was the most attenuated. Single-plaque progenies were derived from the original smallpox vaccines VARIE Sevac (strain Praha) and DRYVAX Wyeth and tested for the above markers and DNA restriction patterns. The results obtained demonstrated biological and molecular heterogeneity of the original virus populations. Close linkage was observed between immunogenic activity and virulence in 3-day but not in 3-week mice. The results indicate that smallpox vaccine preparations may serve as an abundant source of virus mutants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639016     DOI: 10.1016/0264-410x(94)00019-j

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3.

Authors:  J Musil; L Kutinova; K Zurkova; P Hainz; K Babiarova; J Krystofova; S Nemeckova
Journal:  Cancer Gene Ther       Date:  2014-02-21       Impact factor: 5.987

2.  Chemokine binding protein vCCI attenuates vaccinia virus without affecting the cellular response elicited by immunization with a recombinant vaccinia vector carrying the HPV16 E7 gene.

Authors:  Pavel Gabriel; Katarina Babiarova; Kamila Zurkova; Jitka Krystofova; Petr Hainz; Luda Kutinova; Sarka Nemeckova
Journal:  Viral Immunol       Date:  2012-10       Impact factor: 2.257

3.  Attenuation of vaccinia virus by the expression of human Flt3 ligand.

Authors:  Kamila Zurkova; Petr Hainz; Jitka Krystofova; Luda Kutinova; Miloslav Sanda; Sarka Nemeckova
Journal:  Virol J       Date:  2010-05-26       Impact factor: 4.099

4.  Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication.

Authors:  Guiyun Li; Nanhai Chen; Zehua Feng; R Mark L Buller; John Osborne; Tiara Harms; Inger Damon; Chris Upton; David J Esteban
Journal:  Virol J       Date:  2006-10-25       Impact factor: 4.099

5.  The Future of Smallpox Vaccination: is MVA the key?

Authors:  Mark K Slifka
Journal:  Med Immunol       Date:  2005-03-01

Review 6.  ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.

Authors:  Thomas P Monath; Joseph R Caldwell; Wolfgang Mundt; Joan Fusco; Casey S Johnson; Mark Buller; Jian Liu; Bridget Gardner; Greg Downing; Paul S Blum; Tracy Kemp; Richard Nichols; Richard Weltzin
Journal:  Int J Infect Dis       Date:  2004-10       Impact factor: 3.623

7.  Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.

Authors:  Jarmila Knitlova; Vera Hajkova; Ludek Voska; Jana Elsterova; Barbora Obrova; Zora Melkova
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

8.  Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge.

Authors:  Kathleen A Marriott; Christopher V Parkinson; Samantha I Morefield; Robert Davenport; Richard Nichols; Thomas P Monath
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 4.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.